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ABSTRACT
Objectives: The objective of our study was to determine the distribution of different electrophysiological variants of GBS 
and its relationship with albuminocytological dissociation (ACD). The rationale of the study was to determine whether 
presence or absence of albuminocytological dissociation has any association with NCS findings and whether can be relied 
upon as an indirect predictor of axonal variant which warrants poor patient out comes versus demyelinating. Materials 
and Methods: A consecutive series of 76 patients who presented at PIMS over a 12 month period with GBS were 
included. Nerve Conduction studies (NCS) and Electromyographic (EMG) findings with CSF characterization for 
albuminocytological dissociation were recorded. P value < 0.05 was taken significant. Results: NCS revealed AIDP as 
the most common variant (44; 57.8%) followed by AMAN (19; 25%) and AMSAN (7; 9.2%).For 5(6.5%) patients with 
normal NCS, EMG revealed early neuropathic changes in 4 (80% of normal NCS; 5.2% of total) (suggesting axonal 
degeneration). Total axonal degenerative type accounted for (AMAN + AMSAN + axonal neuropathy on EMG=30) 39.4% 
while demyelinating (AIDP + prolonged/absent F-wave=45) 59.2%. ACD was found in 60 (78.9%) patients.There was no 
signification association between ACD and NCS variants (p>0.05). Conclusion: AIDP is the most prevalent (58%) GBS 
variant in our population, at least in the vicinity of Islamabad. There is high prevalence of axonal variants (≈40% of total) 
as compared to Western countries. There is no correlation between ACD and NCS variants. ACD cannot be used as an 
independent predictor of NCS variant. Presence or absence of ACD has no definite predilection for axonal variant which 
itself warrants poor patient outcomes versus demyelinating type. 
Key Words: GullainBarré Syndrome; variants; nerve conduction studies; electromyography; albuminocytological dissociation; 
cerebrospinal fluid, association. 
INTRODUCTION
Acute flaccid paralysis (AFP) has a wide spectrum of 
etiologies.(1,2) One such common preventable cause is 
poliomyelitis which is still being reported in Pakistan. With 
marked decline in the incidence of polio, Guillain-Barré 
syndrome is now a common cause of acute flaccid paralysis. 
Two-thirds of GBS patients develop the neurologic symptoms 
2-4 weeks after respiratory or gastrointestinal infection.(3) 
The initial symptoms are subtleparesthesias in the toes and 
fingertips, followed by lower extremity weakness that may 
ascend over hours to days to involve the arms, cranial 
nerves, and in severe cases the muscles of respiration. 
Respiratory muscle weakness is a poor prognostic sign.(3, 4, 5) 
At some point during their illness, up to 10 percent of 
patients require mechanical ventilation.(6) GBS has several 
electro physiological manifestations and variants namely 
AIDP (Acute Inflammatory Demyelinating Polyneuropathy), 
AMAN (Acute Motor Axonal Neuropathy), AMSAN (Acute 
Motor Sensory Axonal Neuropathy) or normal. Each has its 
own diagnostic and prognostic significance and guides 
management at least to some extent on individual basis.(3, 4, 
5, 6) CSF is characteristically acellular. Protein levels may be 
normal during the first week of the illness, but the majority 
will have an increase in protein if measured 2 or 3 weeks 
later, called albuminocytological dissociation (raised protein 
concentration without pleocytosis).(6) Since the knowledge 
about novel presentations of GBS is currently evolving, one 
must remain abreast not only with the worldwide spectrum 
of GBS but of its local variants, both clinical and electro 
physiological. Meanwhile, the importance of albumino 
cytological dissociationcannot be denied both diagnostically 
and prognostically.(7, 8, 9) The rationale of the study was to 
determine whether presence or absence of albumino 
cytological dissociation has any association with NCS 
findings and whether can be relied upon as an indirect 
predictor of axonal variant which warrants poor patient 
outcomes versus demyelinating. 
MATERIALS AND METHODS
This study was a single-center, observational, descriptive 
study carried out at Department of Neurology, Pakistan 
Institute of Medical Sciences (PIMS), Islamabad, Pakistan; 
from 1st July 2013 to 30th June 2014 i-e-, 12 months 
period. Seventy six patients of GBS aged more than ≥ 12 
years (only adult population is received at our centre) were 
included and analyzed in the final data set. This study was 
an independent project of the department and was not 
funded by any pharmaceutical organization. The study was 
reviewed by ethics committee and performed in 
accordance with the ethical standards laid down in an 
appropriate version of the 2000 Declaration of Helsinki as 
well as the Declaration of Istanbul 2008. Patients fulfilling 
the inclusion criteria were enrolled after taking informed 
written consent from the patients and/ or relatives. All the 
patients were admitted when they first presented to the 
facility without delay. Criterion for GBS was ascertained 
according to Brighton Collaboration criterion for GBS 
(clinical, laboratory and NCS) and the following information 
was collected:(10) age, gender, duration of illness, clinical 
presentation and routine laboratory tests (complete blood 
counts, liver function tests, renal function tests, blood 
sugar random, serum electrolytes, urine routine 
examination, urine culture, blood cultures, arterial blood 
gases (ABGs), electrocardiogram, chest x-rays, toxicology 
screen, ESR, CPK, LDH, hepatitis screening). 
Electrodiagnostic tests i-e-, nerve conduction studies 
(NCS) and electromyography (EMG) were carried out using 
Cadwell Sierra II Wedge NCS EMG machine by a 
neurologist. Electrodiagnostic tests were performed in all 
patients and data was recorded. Lumbar puncture was 
done for CSF R/E (cerebrospinal fluid routine examination) 
in all patients consenting. CSF protein estimation with 
albuminocytological dissociation was calculated. 
Albuminocytological dissociation was defined as CSF with 
raised protein (>45mg/dl; lab reference at our centre) and 
total cell count of ≤ 10/mm3.6 Patients with alcoholism, 
any trauma affecting muscles or nerves, renal or metabolic 
dysfunctions, peripheral vascular diseases, myopathy, 
motor neuron disorders, any genetic or other disorders 
affecting nerve and muscles, CIDP (Chronic Inflammatory 
Demyelinating Polyneuropathy), diabetic peripheral 
neuropathy were excluded. Electrophysiologically, based 
on NCS, the following variants were defined: AIDP (Acute 
Inflammatory Demyelinating Polyneuropathy), AMAN 
(Acute Motor Axonal Neuropathy), AMSAN (Acute Motor 
Sensory Axonal Neuropathy) or normal. The nerve 
conduction studies were performed within 24-72 h of 
hospitalization in all cases. Needle EMG was also 
performed. At least one motor and one sensory nerve were 
tested on the upper and lower limbs. F-wave 
responseswere recorded in all the extremities. Additionally, 
routine motor conduction studies were performed on the 
median, ulnar, peroneal and tibial nerves using 
conventional procedures. Sensory nerve studies were 
performed on the median, ulnar and sural nerves. The 
amplitude of the negative phase was measured for 
compound muscle action potentials and sensory nerve 
action potentials. Patients were classified into AIDP or 
AMAN based on the existing electrodiagnostic criteria.(11) 
AMSAN was defined as the presence of AMAN pattern in 
motor nerve studies with sensory nerve action potential 
amplitude reduction more than 50% of the normal in two 
or more sensory nerves.Millar-Fischer Syndrome (MFS) 
was defined as triad of ataxia, opthamoplegia and areflexia 
without other possible causes.(6) Polyneuritis cranialis was 
defined as that only involving multiple cranial nerves while 
paraparetic as that only involving legs.(6) People were 
offered plasma exchange (PE), Intravenous 
Immunoglobulin (IVIG), PE followed by IVIG or none 
accordingly.  The data was analyzed using SPSS version 
17.0. Mean and standard deviation were calculated for 
numerical variables. Descriptive statistics were used to 
determine frequency and percentages for categorical 
variables and results were expressed either graphically or 
tabulated. Chi-square (x2) test was used and p values were 
calculated. P value < 0.05 was taken significant.
RESULTS
Mean age was 34.7 ± 18.0 years ranging from 12-75 
years. Gender distribution revealed male preponderance; 
59 (77.6%) males and 17 (22.4%) females; 3.5:1. Mean 
duration of illness before presentation to hospital was 9.7 
± 7.6ranging from 4 to 21 days. Most common clinical 
presentation was quadriparetic variety (73 out of 76; 
96.1%). Other variants included one (1.3%) Miller-Fischer, 
one (1.3%) polyneuritis cranialis and one (1.3%) 
paraparetic variant.NCS revealed AIDP as the most 
common variant (44; 57.8%) followed by AMAN (19; 
25%) and AMSAN (7; 9.2%); axonal (AMAN + 
AMSAN=26, 34.2%)(Figure 1).
 
Figure 1: NCS based defined variants of GullainBarré 
Syndrome.AIDP (Acute Inflammatory Demyelinating 
Polyneuropathy), AMAN (Acute Motor Axonal Neuropathy), 
AMSAN (Acute Motor Sensory Axonal Neuropathy).
For 5 (6.5%) patients with normal NCS, EMG revealed 
early neuropathic changes in 4 (80% of normal NCS; 5.2% 
of total) (suggesting axonal degeneration) while one (20% 
of normal NCS; 1.3% of total) proved to be Millar-Fischer 
Syndrome. The remaining one (1.3% of total) only had the 
finding of prolonged/ absent F-wave markers as the sole 
sign of proximal demyelination. Total axonal degenerative 
type accounted for (AMAN + AMSAN + axonal neuropathy 
on EMG=30) 39.4% while demyelinating (AIDP + 
prolonged/absent F-wave=45) 59.2% (Figure 2).
 
Figure 2: NCS and EMG based differentiation of variants 
of GullainBarré Syndrome.
ACD was found in 60 (78.9%) patients.Mean CSF protein 
was 131.1 ± 110 mg/dl ranging from 19 to 467 mg/dl (for 
all patients with CSF reports whether ACD or not). 
However, there was no correlation between ACD and 
NCS/EMG variants (p>0.05) (Table 1). 
Table 1: Relationship of Nerve Conduction Study variants 
with Cerebro Spinal Fluid protein
Table 1: Relationship of Nerve Conduction Study variants 
with Cerebro Spinal Fluid protein. AIDP (Acute 
Inflammatory Demyelinating Polyneuropathy), AMAN 
(Acute Motor Axonal Neuropathy), AMSAN (Acute Motor 
Sensory Axonal Neuropathy), P=prolonged, A=absent.
DISCUSSION
GBS is a common cause of acute flaccid paralysis. 
Distinguishing patients with different variants of GBS from 
one another can be of great prognostic value. Prognosis 
depends on the time of presentation and delay in 
treatment. Despite all improvements in treatment and 
supportive care, the death rate is still around5%, even in 
the best intensive care units.(6) Worldwide, the death rate 
runs slightly higher, mostly from a lack of availability of 
life-support equipment during the lengthy plateau lasting 
four to six weeks and in some cases up to one year, when 
a ventilator is needed in the worst cases.(6) Poor prognostic 
factors include age over 40 years, duration of active 
disease, high CSF protein content, rapid progression of 
motor weakness, preceding diarrheal illness, marked 
disability at presentation, electrophysiological signs of 
axonal neuropathy, requirement ofventilatory support, high 
anti-GM1 titer and poor upper-limb muscle strength.(1, 2, 6, 
7) Incidence of GBS, according to a rough estimate is much 
higher in South-Asia as compared to Europe and America 
and axonal variants account for a much larger proportion. 
(12) An epidemiologic study reported an 8-13% mortality 
rate despite ICU management in GBS, although the rate 
may be less than 5% in tertiary care centers with a team 
of medical professionals who are familiar with GBS 
management.(6) The most prevalent clinical variant, to our 
observation, wasthe quadripareticvariety in which all four 
limbs were involved usually in ascending manner.NCS 
revealed AIDP as the most common variant (44; 57.8%) 
followed by AMAN (19; 25%) and AMSAN (7; 9.2%); 
axonal (AMAN + AMSAN=26, 34.2%) (Figure 1).Upon 
review of data from local literature, Zaheer et al. in 2005 
commented on a set of 25 patients from Lahore region 
that the break down of different patterns of neuropathy 
was 36% demyelinating, 12% axonal and 52% of mixed 
variety having both demyelinating and axonal components. 
(11) They concluded that the pattern of neuropathy in GBS 
is nearly the same as reported in most European and local 
studies except Chinese endemic cases where axonal form 
is more frequent. However, other authors like Khan et al. 
did not concur with their findings.(12) They suggested that 
axonal variants constitute 40% of GBS. The variants, 
according to them were distributed as AIDP-60%, 
AMAN-30% and AMSAN-10% i-e-, axonal-40%. Their data 
set consisted of 40 patients from vicinity of Rawalpindi 
region and their results were much similar to ours when 
reported in 2010.They concluded that a high frequency of 
the axonal variants persists in Pakistan.(12) Siddiqui and 
colleaguesin 2013 studied a group of 29 GBS patients 
having AIDP-62%, AMAN-27.5% and AMSAN-10.3%(≈
axonal-38%) and concluded likewise.(13) A study by 
Yadegariet al.from Tehran, Iran done over a period of 11 
years on 121 GBS patients concluded in 2007a 
distribution pattern of 63%, 23% and 14% of AIDP, AMAN 
and AMSAN respectively (axonal-37%).(14) Meta-analysis 
reports from Europe and the United States state that 
60–80% of people with GBS have demyelinating subtype 
(AIDP) and AMAN affects only a small number 
(6–7%).These reports suggest thatin Asia and Central and 
South America, the proportion of axonal GBS is 
significantly higher (30–65%).(8) Our findings of 
demyelinating variant (AIDP + prolonged/absent 
F-wave=45) being ≈ 59% and axonal (AMAN + AMSAN 
+ axonal neuropathy on EMG=30) ≈ 40% is in 
agreement with these international reports suggesting a 
relatively poor overall prognosis of GBS in our population 
(Figure 2). Our findings support the dictum that there is 
high prevalence of axonal variants (≈40% of total) in our 
population (Asians) as compared to Western countries.(6)
We found that 6.5% NCS were normal and EMG had to be 
done in order to revealearly neuropathic changes of axonal 
degeneration in 4 (66.7% of normal NCS; 5.2% of total). 
This highlights the fact that when NCS does not reveal 
overt demyelination or axonopathy, EMG is mandatory and 
most of the time reveals neuropathic changes even earlier 
in the course of disease suggesting axonal degeneration. A 
paper by Shabbir et al.published in 2012 identified that 
out of a set of 18 patients with axonal GBS, 12 showed 
fibrillation potentials, positive sharp waves and increased 
insertional activity within 4-12 days of symptoms onset 
and 6 beyond that period.(15) Active denervation in the form 
of fibrillation potentials and positive sharp waves were 
noted frequently and decreased interference pattern in 
almost all patients. On the basis of their observations of 
finding fibrillation potentials, positive sharp waves and 
decreased interference pattern early in the course of 
disease i-e-, before two weeks of symptom onset, they 
raised the query for a possible new hyperacute or 
fulminant variant of GBS.(15) The 4 of our patients with 
normal NCS revealed similar earlier changes of axonal 
neuropathy (all NCS/EMG done within 24-72 hours and 
symptom onset in all of these 4 patients being 3-4 days 
only) supporting their idea but needs further confirmation. 
It also suggests that when clinically indicated, NCS should 
be combined by detailed EMG study especially if NCS turns 
out to be normal. In a study by Akbayramet al.done in 36 
children in 2010-11, 51.4% showed albuminocytological 
dissociation on cerebrospinal fluid examination.(6) 
According to Yadegari and colleagues, higher levels of CSF 
protein are more frequent in AIDP subtype. They 
commented that although the rise in CSF protein is more 
frequent in demyelinating variant, it may not have enough 
sensitivity to discriminate AIDP from axonal subtypes. 
Hence, the diagnosis of GBS and defining its subtypes 
should not be made based on a single finding.(14) We found 
ACD in 60 (78.9%) patients with mean CSF protein of 
131.1 ± 110 mg/dl ranging from 19 to 467 mg/dl. 
However, there was no correlation between ACD and 
NCS/EMG variants (p>0.05) (Table 1). Our findings 
therefore concur with that of Yadegariet al.(14) and further 
augments their findings signifying that NCS/EMG are not 
only essential diagnostic tools but prognostic as well by 
helping differentiate between axonal and demyelinating 
typesirrespective of whether ACD is present or not (Table 
1). Classifying patients on the basis of nerve conduction 
studies and electromyography can be helpful in guiding the 
prognosis of GBS in addition to being diagnostically 
pertinent. It helps stratify patients at beginning and thus 
help modify management plans accordingly with the hope 
of better patient outcomes. However, this classification 
should be based on a comprehensive and compact 
agreement between clinical presentation, CSF findings 
and detailed electrophysiological studies and not on a 
single factor. While high CSF is suggested by some to be a 
marker of poor patient outcomes, ADC per se does not 
differ among different NSC variants and mere presence or 
absence of ACD cannot predict axonal or demyelinating 
neuropathy which themselves are independent predictors 
of outcome. 
CONCLUSION 
AIDP is the most prevalent (58%) GBS variant in our 
population, at least in the vicinity of Islamabad. There is 
high prevalence of axonal variants (≈40% of total) as 
compared to Western countries. There is no correlation 
between ACD and NCS variants. ACD cannot be used as 
an independent predictor of NCS variant.Presence or 
absence of ACD has no definite predilection for axonal 
variant which itself warrants poor patient outcomes versus 
demyelinating type. 
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O R I G I N A L  A R T I C L E
INTRODUCTION
Acute flaccid paralysis (AFP) has a wide spectrum of 
etiologies.(1,2) One such common preventable cause is 
poliomyelitis which is still being reported in Pakistan. With 
marked decline in the incidence of polio, Guillain-Barré 
syndrome is now a common cause of acute flaccid paralysis. 
Two-thirds of GBS patients develop the neurologic symptoms 
2-4 weeks after respiratory or gastrointestinal infection.(3) 
The initial symptoms are subtleparesthesias in the toes and 
fingertips, followed by lower extremity weakness that may 
ascend over hours to days to involve the arms, cranial 
nerves, and in severe cases the muscles of respiration. 
Respiratory muscle weakness is a poor prognostic sign.(3, 4, 5) 
At some point during their illness, up to 10 percent of 
patients require mechanical ventilation.(6) GBS has several 
electro physiological manifestations and variants namely 
AIDP (Acute Inflammatory Demyelinating Polyneuropathy), 
AMAN (Acute Motor Axonal Neuropathy), AMSAN (Acute 
Motor Sensory Axonal Neuropathy) or normal. Each has its 
own diagnostic and prognostic significance and guides 
management at least to some extent on individual basis.(3, 4, 
5, 6) CSF is characteristically acellular. Protein levels may be 
normal during the first week of the illness, but the majority 
will have an increase in protein if measured 2 or 3 weeks 
later, called albuminocytological dissociation (raised protein 
concentration without pleocytosis).(6) Since the knowledge 
about novel presentations of GBS is currently evolving, one 
must remain abreast not only with the worldwide spectrum 
of GBS but of its local variants, both clinical and electro 
physiological. Meanwhile, the importance of albumino 
cytological dissociationcannot be denied both diagnostically 
and prognostically.(7, 8, 9) The rationale of the study was to 
determine whether presence or absence of albumino 
cytological dissociation has any association with NCS 
findings and whether can be relied upon as an indirect 
predictor of axonal variant which warrants poor patient 
outcomes versus demyelinating. 
MATERIALS AND METHODS
This study was a single-center, observational, descriptive 
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study carried out at Department of Neurology, Pakistan 
Institute of Medical Sciences (PIMS), Islamabad, Pakistan; 
from 1st July 2013 to 30th June 2014 i-e-, 12 months 
period. Seventy six patients of GBS aged more than ≥ 12 
years (only adult population is received at our centre) were 
included and analyzed in the final data set. This study was 
an independent project of the department and was not 
funded by any pharmaceutical organization. The study was 
reviewed by ethics committee and performed in 
accordance with the ethical standards laid down in an 
appropriate version of the 2000 Declaration of Helsinki as 
well as the Declaration of Istanbul 2008. Patients fulfilling 
the inclusion criteria were enrolled after taking informed 
written consent from the patients and/ or relatives. All the 
patients were admitted when they first presented to the 
facility without delay. Criterion for GBS was ascertained 
according to Brighton Collaboration criterion for GBS 
(clinical, laboratory and NCS) and the following information 
was collected:(10) age, gender, duration of illness, clinical 
presentation and routine laboratory tests (complete blood 
counts, liver function tests, renal function tests, blood 
sugar random, serum electrolytes, urine routine 
examination, urine culture, blood cultures, arterial blood 
gases (ABGs), electrocardiogram, chest x-rays, toxicology 
screen, ESR, CPK, LDH, hepatitis screening). 
Electrodiagnostic tests i-e-, nerve conduction studies 
(NCS) and electromyography (EMG) were carried out using 
Cadwell Sierra II Wedge NCS EMG machine by a 
neurologist. Electrodiagnostic tests were performed in all 
patients and data was recorded. Lumbar puncture was 
done for CSF R/E (cerebrospinal fluid routine examination) 
in all patients consenting. CSF protein estimation with 
albuminocytological dissociation was calculated. 
Albuminocytological dissociation was defined as CSF with 
raised protein (>45mg/dl; lab reference at our centre) and 
total cell count of ≤ 10/mm3.6 Patients with alcoholism, 
any trauma affecting muscles or nerves, renal or metabolic 
dysfunctions, peripheral vascular diseases, myopathy, 
motor neuron disorders, any genetic or other disorders 
affecting nerve and muscles, CIDP (Chronic Inflammatory 
Demyelinating Polyneuropathy), diabetic peripheral 
neuropathy were excluded. Electrophysiologically, based 
on NCS, the following variants were defined: AIDP (Acute 
Inflammatory Demyelinating Polyneuropathy), AMAN 
(Acute Motor Axonal Neuropathy), AMSAN (Acute Motor 
Sensory Axonal Neuropathy) or normal. The nerve 
conduction studies were performed within 24-72 h of 
hospitalization in all cases. Needle EMG was also 
performed. At least one motor and one sensory nerve were 
tested on the upper and lower limbs. F-wave 
responseswere recorded in all the extremities. Additionally, 
routine motor conduction studies were performed on the 
median, ulnar, peroneal and tibial nerves using 
conventional procedures. Sensory nerve studies were 
performed on the median, ulnar and sural nerves. The 
amplitude of the negative phase was measured for 
compound muscle action potentials and sensory nerve 
action potentials. Patients were classified into AIDP or 
AMAN based on the existing electrodiagnostic criteria.(11) 
AMSAN was defined as the presence of AMAN pattern in 
motor nerve studies with sensory nerve action potential 
amplitude reduction more than 50% of the normal in two 
or more sensory nerves.Millar-Fischer Syndrome (MFS) 
was defined as triad of ataxia, opthamoplegia and areflexia 
without other possible causes.(6) Polyneuritis cranialis was 
defined as that only involving multiple cranial nerves while 
paraparetic as that only involving legs.(6) People were 
offered plasma exchange (PE), Intravenous 
Immunoglobulin (IVIG), PE followed by IVIG or none 
accordingly.  The data was analyzed using SPSS version 
17.0. Mean and standard deviation were calculated for 
numerical variables. Descriptive statistics were used to 
determine frequency and percentages for categorical 
variables and results were expressed either graphically or 
tabulated. Chi-square (x2) test was used and p values were 
calculated. P value < 0.05 was taken significant.
RESULTS
Mean age was 34.7 ± 18.0 years ranging from 12-75 
years. Gender distribution revealed male preponderance; 
59 (77.6%) males and 17 (22.4%) females; 3.5:1. Mean 
duration of illness before presentation to hospital was 9.7 
± 7.6ranging from 4 to 21 days. Most common clinical 
presentation was quadriparetic variety (73 out of 76; 
96.1%). Other variants included one (1.3%) Miller-Fischer, 
one (1.3%) polyneuritis cranialis and one (1.3%) 
paraparetic variant.NCS revealed AIDP as the most 
common variant (44; 57.8%) followed by AMAN (19; 
25%) and AMSAN (7; 9.2%); axonal (AMAN + 
AMSAN=26, 34.2%)(Figure 1).
 
Figure 1: NCS based defined variants of GullainBarré 
Syndrome.AIDP (Acute Inflammatory Demyelinating 
Polyneuropathy), AMAN (Acute Motor Axonal Neuropathy), 
AMSAN (Acute Motor Sensory Axonal Neuropathy).
For 5 (6.5%) patients with normal NCS, EMG revealed 
early neuropathic changes in 4 (80% of normal NCS; 5.2% 
of total) (suggesting axonal degeneration) while one (20% 
of normal NCS; 1.3% of total) proved to be Millar-Fischer 
Syndrome. The remaining one (1.3% of total) only had the 
finding of prolonged/ absent F-wave markers as the sole 
sign of proximal demyelination. Total axonal degenerative 
type accounted for (AMAN + AMSAN + axonal neuropathy 
on EMG=30) 39.4% while demyelinating (AIDP + 
prolonged/absent F-wave=45) 59.2% (Figure 2).
 
Figure 2: NCS and EMG based differentiation of variants 
of GullainBarré Syndrome.
ACD was found in 60 (78.9%) patients.Mean CSF protein 
was 131.1 ± 110 mg/dl ranging from 19 to 467 mg/dl (for 
all patients with CSF reports whether ACD or not). 
However, there was no correlation between ACD and 
NCS/EMG variants (p>0.05) (Table 1). 
Table 1: Relationship of Nerve Conduction Study variants 
with Cerebro Spinal Fluid protein
Table 1: Relationship of Nerve Conduction Study variants 
with Cerebro Spinal Fluid protein. AIDP (Acute 
Inflammatory Demyelinating Polyneuropathy), AMAN 
(Acute Motor Axonal Neuropathy), AMSAN (Acute Motor 
Sensory Axonal Neuropathy), P=prolonged, A=absent.
DISCUSSION
GBS is a common cause of acute flaccid paralysis. 
Distinguishing patients with different variants of GBS from 
one another can be of great prognostic value. Prognosis 
depends on the time of presentation and delay in 
treatment. Despite all improvements in treatment and 
supportive care, the death rate is still around5%, even in 
the best intensive care units.(6) Worldwide, the death rate 
runs slightly higher, mostly from a lack of availability of 
life-support equipment during the lengthy plateau lasting 
four to six weeks and in some cases up to one year, when 
a ventilator is needed in the worst cases.(6) Poor prognostic 
factors include age over 40 years, duration of active 
disease, high CSF protein content, rapid progression of 
motor weakness, preceding diarrheal illness, marked 
disability at presentation, electrophysiological signs of 
axonal neuropathy, requirement ofventilatory support, high 
anti-GM1 titer and poor upper-limb muscle strength.(1, 2, 6, 
7) Incidence of GBS, according to a rough estimate is much 
higher in South-Asia as compared to Europe and America 
and axonal variants account for a much larger proportion. 
(12) An epidemiologic study reported an 8-13% mortality 
rate despite ICU management in GBS, although the rate 
may be less than 5% in tertiary care centers with a team 
of medical professionals who are familiar with GBS 
management.(6) The most prevalent clinical variant, to our 
observation, wasthe quadripareticvariety in which all four 
limbs were involved usually in ascending manner.NCS 
revealed AIDP as the most common variant (44; 57.8%) 
followed by AMAN (19; 25%) and AMSAN (7; 9.2%); 
axonal (AMAN + AMSAN=26, 34.2%) (Figure 1).Upon 
review of data from local literature, Zaheer et al. in 2005 
commented on a set of 25 patients from Lahore region 
that the break down of different patterns of neuropathy 
was 36% demyelinating, 12% axonal and 52% of mixed 
variety having both demyelinating and axonal components. 
(11) They concluded that the pattern of neuropathy in GBS 
is nearly the same as reported in most European and local 
studies except Chinese endemic cases where axonal form 
is more frequent. However, other authors like Khan et al. 
did not concur with their findings.(12) They suggested that 
axonal variants constitute 40% of GBS. The variants, 
according to them were distributed as AIDP-60%, 
AMAN-30% and AMSAN-10% i-e-, axonal-40%. Their data 
set consisted of 40 patients from vicinity of Rawalpindi 
region and their results were much similar to ours when 
reported in 2010.They concluded that a high frequency of 
the axonal variants persists in Pakistan.(12) Siddiqui and 
colleaguesin 2013 studied a group of 29 GBS patients 
having AIDP-62%, AMAN-27.5% and AMSAN-10.3%(≈
axonal-38%) and concluded likewise.(13) A study by 
Yadegariet al.from Tehran, Iran done over a period of 11 
years on 121 GBS patients concluded in 2007a 
distribution pattern of 63%, 23% and 14% of AIDP, AMAN 
and AMSAN respectively (axonal-37%).(14) Meta-analysis 
reports from Europe and the United States state that 
60–80% of people with GBS have demyelinating subtype 
(AIDP) and AMAN affects only a small number 
(6–7%).These reports suggest thatin Asia and Central and 
South America, the proportion of axonal GBS is 
significantly higher (30–65%).(8) Our findings of 
demyelinating variant (AIDP + prolonged/absent 
F-wave=45) being ≈ 59% and axonal (AMAN + AMSAN 
+ axonal neuropathy on EMG=30) ≈ 40% is in 
agreement with these international reports suggesting a 
relatively poor overall prognosis of GBS in our population 
(Figure 2). Our findings support the dictum that there is 
high prevalence of axonal variants (≈40% of total) in our 
population (Asians) as compared to Western countries.(6)
We found that 6.5% NCS were normal and EMG had to be 
done in order to revealearly neuropathic changes of axonal 
degeneration in 4 (66.7% of normal NCS; 5.2% of total). 
This highlights the fact that when NCS does not reveal 
overt demyelination or axonopathy, EMG is mandatory and 
most of the time reveals neuropathic changes even earlier 
in the course of disease suggesting axonal degeneration. A 
paper by Shabbir et al.published in 2012 identified that 
out of a set of 18 patients with axonal GBS, 12 showed 
fibrillation potentials, positive sharp waves and increased 
insertional activity within 4-12 days of symptoms onset 
and 6 beyond that period.(15) Active denervation in the form 
of fibrillation potentials and positive sharp waves were 
noted frequently and decreased interference pattern in 
almost all patients. On the basis of their observations of 
finding fibrillation potentials, positive sharp waves and 
decreased interference pattern early in the course of 
disease i-e-, before two weeks of symptom onset, they 
raised the query for a possible new hyperacute or 
fulminant variant of GBS.(15) The 4 of our patients with 
normal NCS revealed similar earlier changes of axonal 
neuropathy (all NCS/EMG done within 24-72 hours and 
symptom onset in all of these 4 patients being 3-4 days 
only) supporting their idea but needs further confirmation. 
It also suggests that when clinically indicated, NCS should 
be combined by detailed EMG study especially if NCS turns 
out to be normal. In a study by Akbayramet al.done in 36 
children in 2010-11, 51.4% showed albuminocytological 
dissociation on cerebrospinal fluid examination.(6) 
According to Yadegari and colleagues, higher levels of CSF 
protein are more frequent in AIDP subtype. They 
commented that although the rise in CSF protein is more 
frequent in demyelinating variant, it may not have enough 
sensitivity to discriminate AIDP from axonal subtypes. 
Hence, the diagnosis of GBS and defining its subtypes 
should not be made based on a single finding.(14) We found 
ACD in 60 (78.9%) patients with mean CSF protein of 
131.1 ± 110 mg/dl ranging from 19 to 467 mg/dl. 
However, there was no correlation between ACD and 
NCS/EMG variants (p>0.05) (Table 1). Our findings 
therefore concur with that of Yadegariet al.(14) and further 
augments their findings signifying that NCS/EMG are not 
only essential diagnostic tools but prognostic as well by 
helping differentiate between axonal and demyelinating 
typesirrespective of whether ACD is present or not (Table 
1). Classifying patients on the basis of nerve conduction 
studies and electromyography can be helpful in guiding the 
prognosis of GBS in addition to being diagnostically 
pertinent. It helps stratify patients at beginning and thus 
help modify management plans accordingly with the hope 
of better patient outcomes. However, this classification 
should be based on a comprehensive and compact 
agreement between clinical presentation, CSF findings 
and detailed electrophysiological studies and not on a 
single factor. While high CSF is suggested by some to be a 
marker of poor patient outcomes, ADC per se does not 
differ among different NSC variants and mere presence or 
absence of ACD cannot predict axonal or demyelinating 
neuropathy which themselves are independent predictors 
of outcome. 
CONCLUSION 
AIDP is the most prevalent (58%) GBS variant in our 
population, at least in the vicinity of Islamabad. There is 
high prevalence of axonal variants (≈40% of total) as 
compared to Western countries. There is no correlation 
between ACD and NCS variants. ACD cannot be used as 
an independent predictor of NCS variant.Presence or 
absence of ACD has no definite predilection for axonal 
variant which itself warrants poor patient outcomes versus 
demyelinating type. 
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INTRODUCTION
Acute flaccid paralysis (AFP) has a wide spectrum of 
etiologies.(1,2) One such common preventable cause is 
poliomyelitis which is still being reported in Pakistan. With 
marked decline in the incidence of polio, Guillain-Barré 
syndrome is now a common cause of acute flaccid paralysis. 
Two-thirds of GBS patients develop the neurologic symptoms 
2-4 weeks after respiratory or gastrointestinal infection.(3) 
The initial symptoms are subtleparesthesias in the toes and 
fingertips, followed by lower extremity weakness that may 
ascend over hours to days to involve the arms, cranial 
nerves, and in severe cases the muscles of respiration. 
Respiratory muscle weakness is a poor prognostic sign.(3, 4, 5) 
At some point during their illness, up to 10 percent of 
patients require mechanical ventilation.(6) GBS has several 
electro physiological manifestations and variants namely 
AIDP (Acute Inflammatory Demyelinating Polyneuropathy), 
AMAN (Acute Motor Axonal Neuropathy), AMSAN (Acute 
Motor Sensory Axonal Neuropathy) or normal. Each has its 
own diagnostic and prognostic significance and guides 
management at least to some extent on individual basis.(3, 4, 
5, 6) CSF is characteristically acellular. Protein levels may be 
normal during the first week of the illness, but the majority 
will have an increase in protein if measured 2 or 3 weeks 
later, called albuminocytological dissociation (raised protein 
concentration without pleocytosis).(6) Since the knowledge 
about novel presentations of GBS is currently evolving, one 
must remain abreast not only with the worldwide spectrum 
of GBS but of its local variants, both clinical and electro 
physiological. Meanwhile, the importance of albumino 
cytological dissociationcannot be denied both diagnostically 
and prognostically.(7, 8, 9) The rationale of the study was to 
determine whether presence or absence of albumino 
cytological dissociation has any association with NCS 
findings and whether can be relied upon as an indirect 
predictor of axonal variant which warrants poor patient 
outcomes versus demyelinating. 
MATERIALS AND METHODS
This study was a single-center, observational, descriptive 
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study carried out at Department of Neurology, Pakistan 
Institute of Medical Sciences (PIMS), Islamabad, Pakistan; 
from 1st July 2013 to 30th June 2014 i-e-, 12 months 
period. Seventy six patients of GBS aged more than ≥ 12 
years (only adult population is received at our centre) were 
included and analyzed in the final data set. This study was 
an independent project of the department and was not 
funded by any pharmaceutical organization. The study was 
reviewed by ethics committee and performed in 
accordance with the ethical standards laid down in an 
appropriate version of the 2000 Declaration of Helsinki as 
well as the Declaration of Istanbul 2008. Patients fulfilling 
the inclusion criteria were enrolled after taking informed 
written consent from the patients and/ or relatives. All the 
patients were admitted when they first presented to the 
facility without delay. Criterion for GBS was ascertained 
according to Brighton Collaboration criterion for GBS 
(clinical, laboratory and NCS) and the following information 
was collected:(10) age, gender, duration of illness, clinical 
presentation and routine laboratory tests (complete blood 
counts, liver function tests, renal function tests, blood 
sugar random, serum electrolytes, urine routine 
examination, urine culture, blood cultures, arterial blood 
gases (ABGs), electrocardiogram, chest x-rays, toxicology 
screen, ESR, CPK, LDH, hepatitis screening). 
Electrodiagnostic tests i-e-, nerve conduction studies 
(NCS) and electromyography (EMG) were carried out using 
Cadwell Sierra II Wedge NCS EMG machine by a 
neurologist. Electrodiagnostic tests were performed in all 
patients and data was recorded. Lumbar puncture was 
done for CSF R/E (cerebrospinal fluid routine examination) 
in all patients consenting. CSF protein estimation with 
albuminocytological dissociation was calculated. 
Albuminocytological dissociation was defined as CSF with 
raised protein (>45mg/dl; lab reference at our centre) and 
total cell count of ≤ 10/mm3.6 Patients with alcoholism, 
any trauma affecting muscles or nerves, renal or metabolic 
dysfunctions, peripheral vascular diseases, myopathy, 
motor neuron disorders, any genetic or other disorders 
affecting nerve and muscles, CIDP (Chronic Inflammatory 
Demyelinating Polyneuropathy), diabetic peripheral 
neuropathy were excluded. Electrophysiologically, based 
on NCS, the following variants were defined: AIDP (Acute 
Inflammatory Demyelinating Polyneuropathy), AMAN 
(Acute Motor Axonal Neuropathy), AMSAN (Acute Motor 
Sensory Axonal Neuropathy) or normal. The nerve 
conduction studies were performed within 24-72 h of 
hospitalization in all cases. Needle EMG was also 
performed. At least one motor and one sensory nerve were 
tested on the upper and lower limbs. F-wave 
responseswere recorded in all the extremities. Additionally, 
routine motor conduction studies were performed on the 
median, ulnar, peroneal and tibial nerves using 
conventional procedures. Sensory nerve studies were 
performed on the median, ulnar and sural nerves. The 
amplitude of the negative phase was measured for 
compound muscle action potentials and sensory nerve 
action potentials. Patients were classified into AIDP or 
AMAN based on the existing electrodiagnostic criteria.(11) 
AMSAN was defined as the presence of AMAN pattern in 
motor nerve studies with sensory nerve action potential 
amplitude reduction more than 50% of the normal in two 
or more sensory nerves.Millar-Fischer Syndrome (MFS) 
was defined as triad of ataxia, opthamoplegia and areflexia 
without other possible causes.(6) Polyneuritis cranialis was 
defined as that only involving multiple cranial nerves while 
paraparetic as that only involving legs.(6) People were 
offered plasma exchange (PE), Intravenous 
Immunoglobulin (IVIG), PE followed by IVIG or none 
accordingly.  The data was analyzed using SPSS version 
17.0. Mean and standard deviation were calculated for 
numerical variables. Descriptive statistics were used to 
determine frequency and percentages for categorical 
variables and results were expressed either graphically or 
tabulated. Chi-square (x2) test was used and p values were 
calculated. P value < 0.05 was taken significant.
RESULTS
Mean age was 34.7 ± 18.0 years ranging from 12-75 
years. Gender distribution revealed male preponderance; 
59 (77.6%) males and 17 (22.4%) females; 3.5:1. Mean 
duration of illness before presentation to hospital was 9.7 
± 7.6ranging from 4 to 21 days. Most common clinical 
presentation was quadriparetic variety (73 out of 76; 
96.1%). Other variants included one (1.3%) Miller-Fischer, 
one (1.3%) polyneuritis cranialis and one (1.3%) 
paraparetic variant.NCS revealed AIDP as the most 
common variant (44; 57.8%) followed by AMAN (19; 
25%) and AMSAN (7; 9.2%); axonal (AMAN + 
AMSAN=26, 34.2%)(Figure 1).
 
Figure 1: NCS based defined variants of GullainBarré 
Syndrome.AIDP (Acute Inflammatory Demyelinating 
Polyneuropathy), AMAN (Acute Motor Axonal Neuropathy), 
AMSAN (Acute Motor Sensory Axonal Neuropathy).
For 5 (6.5%) patients with normal NCS, EMG revealed 
early neuropathic changes in 4 (80% of normal NCS; 5.2% 
of total) (suggesting axonal degeneration) while one (20% 
of normal NCS; 1.3% of total) proved to be Millar-Fischer 
Syndrome. The remaining one (1.3% of total) only had the 
finding of prolonged/ absent F-wave markers as the sole 
sign of proximal demyelination. Total axonal degenerative 
type accounted for (AMAN + AMSAN + axonal neuropathy 
on EMG=30) 39.4% while demyelinating (AIDP + 
prolonged/absent F-wave=45) 59.2% (Figure 2).
 
Figure 2: NCS and EMG based differentiation of variants 
of GullainBarré Syndrome.
ACD was found in 60 (78.9%) patients.Mean CSF protein 
was 131.1 ± 110 mg/dl ranging from 19 to 467 mg/dl (for 
all patients with CSF reports whether ACD or not). 
However, there was no correlation between ACD and 
NCS/EMG variants (p>0.05) (Table 1). 
Table 1: Relationship of Nerve Conduction Study variants 
with Cerebro Spinal Fluid protein
Table 1: Relationship of Nerve Conduction Study variants 
with Cerebro Spinal Fluid protein. AIDP (Acute 
Inflammatory Demyelinating Polyneuropathy), AMAN 
(Acute Motor Axonal Neuropathy), AMSAN (Acute Motor 
Sensory Axonal Neuropathy), P=prolonged, A=absent.
DISCUSSION
GBS is a common cause of acute flaccid paralysis. 
Distinguishing patients with different variants of GBS from 
one another can be of great prognostic value. Prognosis 
depends on the time of presentation and delay in 
treatment. Despite all improvements in treatment and 
supportive care, the death rate is still around5%, even in 
the best intensive care units.(6) Worldwide, the death rate 
runs slightly higher, mostly from a lack of availability of 
life-support equipment during the lengthy plateau lasting 
four to six weeks and in some cases up to one year, when 
a ventilator is needed in the worst cases.(6) Poor prognostic 
factors include age over 40 years, duration of active 
disease, high CSF protein content, rapid progression of 
motor weakness, preceding diarrheal illness, marked 
disability at presentation, electrophysiological signs of 
axonal neuropathy, requirement ofventilatory support, high 
anti-GM1 titer and poor upper-limb muscle strength.(1, 2, 6, 
7) Incidence of GBS, according to a rough estimate is much 
higher in South-Asia as compared to Europe and America 
and axonal variants account for a much larger proportion. 
(12) An epidemiologic study reported an 8-13% mortality 
rate despite ICU management in GBS, although the rate 
may be less than 5% in tertiary care centers with a team 
of medical professionals who are familiar with GBS 
management.(6) The most prevalent clinical variant, to our 
observation, wasthe quadripareticvariety in which all four 
limbs were involved usually in ascending manner.NCS 
revealed AIDP as the most common variant (44; 57.8%) 
followed by AMAN (19; 25%) and AMSAN (7; 9.2%); 
axonal (AMAN + AMSAN=26, 34.2%) (Figure 1).Upon 
review of data from local literature, Zaheer et al. in 2005 
commented on a set of 25 patients from Lahore region 
that the break down of different patterns of neuropathy 
was 36% demyelinating, 12% axonal and 52% of mixed 
variety having both demyelinating and axonal components. 
(11) They concluded that the pattern of neuropathy in GBS 
is nearly the same as reported in most European and local 
studies except Chinese endemic cases where axonal form 
is more frequent. However, other authors like Khan et al. 
did not concur with their findings.(12) They suggested that 
axonal variants constitute 40% of GBS. The variants, 
according to them were distributed as AIDP-60%, 
AMAN-30% and AMSAN-10% i-e-, axonal-40%. Their data 
set consisted of 40 patients from vicinity of Rawalpindi 
region and their results were much similar to ours when 
reported in 2010.They concluded that a high frequency of 
the axonal variants persists in Pakistan.(12) Siddiqui and 
colleaguesin 2013 studied a group of 29 GBS patients 
having AIDP-62%, AMAN-27.5% and AMSAN-10.3%(≈
axonal-38%) and concluded likewise.(13) A study by 
Yadegariet al.from Tehran, Iran done over a period of 11 
years on 121 GBS patients concluded in 2007a 
distribution pattern of 63%, 23% and 14% of AIDP, AMAN 
and AMSAN respectively (axonal-37%).(14) Meta-analysis 
reports from Europe and the United States state that 
60–80% of people with GBS have demyelinating subtype 
(AIDP) and AMAN affects only a small number 
(6–7%).These reports suggest thatin Asia and Central and 
South America, the proportion of axonal GBS is 
significantly higher (30–65%).(8) Our findings of 
demyelinating variant (AIDP + prolonged/absent 
F-wave=45) being ≈ 59% and axonal (AMAN + AMSAN 
+ axonal neuropathy on EMG=30) ≈ 40% is in 
agreement with these international reports suggesting a 
relatively poor overall prognosis of GBS in our population 
(Figure 2). Our findings support the dictum that there is 
high prevalence of axonal variants (≈40% of total) in our 
population (Asians) as compared to Western countries.(6)
We found that 6.5% NCS were normal and EMG had to be 
done in order to revealearly neuropathic changes of axonal 
degeneration in 4 (66.7% of normal NCS; 5.2% of total). 
This highlights the fact that when NCS does not reveal 
overt demyelination or axonopathy, EMG is mandatory and 
most of the time reveals neuropathic changes even earlier 
in the course of disease suggesting axonal degeneration. A 
paper by Shabbir et al.published in 2012 identified that 
out of a set of 18 patients with axonal GBS, 12 showed 
fibrillation potentials, positive sharp waves and increased 
insertional activity within 4-12 days of symptoms onset 
and 6 beyond that period.(15) Active denervation in the form 
of fibrillation potentials and positive sharp waves were 
noted frequently and decreased interference pattern in 
almost all patients. On the basis of their observations of 
finding fibrillation potentials, positive sharp waves and 
decreased interference pattern early in the course of 
disease i-e-, before two weeks of symptom onset, they 
raised the query for a possible new hyperacute or 
fulminant variant of GBS.(15) The 4 of our patients with 
normal NCS revealed similar earlier changes of axonal 
neuropathy (all NCS/EMG done within 24-72 hours and 
symptom onset in all of these 4 patients being 3-4 days 
only) supporting their idea but needs further confirmation. 
It also suggests that when clinically indicated, NCS should 
be combined by detailed EMG study especially if NCS turns 
out to be normal. In a study by Akbayramet al.done in 36 
children in 2010-11, 51.4% showed albuminocytological 
dissociation on cerebrospinal fluid examination.(6) 
According to Yadegari and colleagues, higher levels of CSF 
protein are more frequent in AIDP subtype. They 
commented that although the rise in CSF protein is more 
frequent in demyelinating variant, it may not have enough 
sensitivity to discriminate AIDP from axonal subtypes. 
Hence, the diagnosis of GBS and defining its subtypes 
should not be made based on a single finding.(14) We found 
ACD in 60 (78.9%) patients with mean CSF protein of 
131.1 ± 110 mg/dl ranging from 19 to 467 mg/dl. 
However, there was no correlation between ACD and 
NCS/EMG variants (p>0.05) (Table 1). Our findings 
therefore concur with that of Yadegariet al.(14) and further 
augments their findings signifying that NCS/EMG are not 
only essential diagnostic tools but prognostic as well by 
helping differentiate between axonal and demyelinating 
typesirrespective of whether ACD is present or not (Table 
1). Classifying patients on the basis of nerve conduction 
studies and electromyography can be helpful in guiding the 
prognosis of GBS in addition to being diagnostically 
pertinent. It helps stratify patients at beginning and thus 
help modify management plans accordingly with the hope 
of better patient outcomes. However, this classification 
should be based on a comprehensive and compact 
agreement between clinical presentation, CSF findings 
and detailed electrophysiological studies and not on a 
single factor. While high CSF is suggested by some to be a 
marker of poor patient outcomes, ADC per se does not 
differ among different NSC variants and mere presence or 
absence of ACD cannot predict axonal or demyelinating 
neuropathy which themselves are independent predictors 
of outcome. 
CONCLUSION 
AIDP is the most prevalent (58%) GBS variant in our 
population, at least in the vicinity of Islamabad. There is 
high prevalence of axonal variants (≈40% of total) as 
compared to Western countries. There is no correlation 
between ACD and NCS variants. ACD cannot be used as 
an independent predictor of NCS variant.Presence or 
absence of ACD has no definite predilection for axonal 
variant which itself warrants poor patient outcomes versus 
demyelinating type. 
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Electrophysiological variant Albuminocytological 
dissociation in CSF 
Statistical 
signiﬁcance 
 Yes n (%) No n (%) p value 
NCS deﬁned variant    
AIDP 37 (61.7) 7 (43.7) 0.32 
AMAN 15 (25) 4 (25) 
AMSAN 4 (6.7) 3 (18.7) 
Normal 3 (5.0) 2 (12.5) 
Only P/A F-wave 1 (1.7) 0 (0) 
Total 60 (100) 16 (100) 
    
NCS plus EMG differentiation    
Demyelinating 38 (63.3) 7 (43.7) 0.10 
Axonal 22 (36.7) 8 (50) 
Normal 0 (0) 1 (6.2) 
Total 60 (100) 16 (100) 
INTRODUCTION
Acute flaccid paralysis (AFP) has a wide spectrum of 
etiologies.(1,2) One such common preventable cause is 
poliomyelitis which is still being reported in Pakistan. With 
marked decline in the incidence of polio, Guillain-Barré 
syndrome is now a common cause of acute flaccid paralysis. 
Two-thirds of GBS patients develop the neurologic symptoms 
2-4 weeks after respiratory or gastrointestinal infection.(3) 
The initial symptoms are subtleparesthesias in the toes and 
fingertips, followed by lower extremity weakness that may 
ascend over hours to days to involve the arms, cranial 
nerves, and in severe cases the muscles of respiration. 
Respiratory muscle weakness is a poor prognostic sign.(3, 4, 5) 
At some point during their illness, up to 10 percent of 
patients require mechanical ventilation.(6) GBS has several 
electro physiological manifestations and variants namely 
AIDP (Acute Inflammatory Demyelinating Polyneuropathy), 
AMAN (Acute Motor Axonal Neuropathy), AMSAN (Acute 
Motor Sensory Axonal Neuropathy) or normal. Each has its 
own diagnostic and prognostic significance and guides 
management at least to some extent on individual basis.(3, 4, 
5, 6) CSF is characteristically acellular. Protein levels may be 
normal during the first week of the illness, but the majority 
will have an increase in protein if measured 2 or 3 weeks 
later, called albuminocytological dissociation (raised protein 
concentration without pleocytosis).(6) Since the knowledge 
about novel presentations of GBS is currently evolving, one 
must remain abreast not only with the worldwide spectrum 
of GBS but of its local variants, both clinical and electro 
physiological. Meanwhile, the importance of albumino 
cytological dissociationcannot be denied both diagnostically 
and prognostically.(7, 8, 9) The rationale of the study was to 
determine whether presence or absence of albumino 
cytological dissociation has any association with NCS 
findings and whether can be relied upon as an indirect 
predictor of axonal variant which warrants poor patient 
outcomes versus demyelinating. 
MATERIALS AND METHODS
This study was a single-center, observational, descriptive 
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study carried out at Department of Neurology, Pakistan 
Institute of Medical Sciences (PIMS), Islamabad, Pakistan; 
from 1st July 2013 to 30th June 2014 i-e-, 12 months 
period. Seventy six patients of GBS aged more than ≥ 12 
years (only adult population is received at our centre) were 
included and analyzed in the final data set. This study was 
an independent project of the department and was not 
funded by any pharmaceutical organization. The study was 
reviewed by ethics committee and performed in 
accordance with the ethical standards laid down in an 
appropriate version of the 2000 Declaration of Helsinki as 
well as the Declaration of Istanbul 2008. Patients fulfilling 
the inclusion criteria were enrolled after taking informed 
written consent from the patients and/ or relatives. All the 
patients were admitted when they first presented to the 
facility without delay. Criterion for GBS was ascertained 
according to Brighton Collaboration criterion for GBS 
(clinical, laboratory and NCS) and the following information 
was collected:(10) age, gender, duration of illness, clinical 
presentation and routine laboratory tests (complete blood 
counts, liver function tests, renal function tests, blood 
sugar random, serum electrolytes, urine routine 
examination, urine culture, blood cultures, arterial blood 
gases (ABGs), electrocardiogram, chest x-rays, toxicology 
screen, ESR, CPK, LDH, hepatitis screening). 
Electrodiagnostic tests i-e-, nerve conduction studies 
(NCS) and electromyography (EMG) were carried out using 
Cadwell Sierra II Wedge NCS EMG machine by a 
neurologist. Electrodiagnostic tests were performed in all 
patients and data was recorded. Lumbar puncture was 
done for CSF R/E (cerebrospinal fluid routine examination) 
in all patients consenting. CSF protein estimation with 
albuminocytological dissociation was calculated. 
Albuminocytological dissociation was defined as CSF with 
raised protein (>45mg/dl; lab reference at our centre) and 
total cell count of ≤ 10/mm3.6 Patients with alcoholism, 
any trauma affecting muscles or nerves, renal or metabolic 
dysfunctions, peripheral vascular diseases, myopathy, 
motor neuron disorders, any genetic or other disorders 
affecting nerve and muscles, CIDP (Chronic Inflammatory 
Demyelinating Polyneuropathy), diabetic peripheral 
neuropathy were excluded. Electrophysiologically, based 
on NCS, the following variants were defined: AIDP (Acute 
Inflammatory Demyelinating Polyneuropathy), AMAN 
(Acute Motor Axonal Neuropathy), AMSAN (Acute Motor 
Sensory Axonal Neuropathy) or normal. The nerve 
conduction studies were performed within 24-72 h of 
hospitalization in all cases. Needle EMG was also 
performed. At least one motor and one sensory nerve were 
tested on the upper and lower limbs. F-wave 
responseswere recorded in all the extremities. Additionally, 
routine motor conduction studies were performed on the 
median, ulnar, peroneal and tibial nerves using 
conventional procedures. Sensory nerve studies were 
performed on the median, ulnar and sural nerves. The 
amplitude of the negative phase was measured for 
compound muscle action potentials and sensory nerve 
action potentials. Patients were classified into AIDP or 
AMAN based on the existing electrodiagnostic criteria.(11) 
AMSAN was defined as the presence of AMAN pattern in 
motor nerve studies with sensory nerve action potential 
amplitude reduction more than 50% of the normal in two 
or more sensory nerves.Millar-Fischer Syndrome (MFS) 
was defined as triad of ataxia, opthamoplegia and areflexia 
without other possible causes.(6) Polyneuritis cranialis was 
defined as that only involving multiple cranial nerves while 
paraparetic as that only involving legs.(6) People were 
offered plasma exchange (PE), Intravenous 
Immunoglobulin (IVIG), PE followed by IVIG or none 
accordingly.  The data was analyzed using SPSS version 
17.0. Mean and standard deviation were calculated for 
numerical variables. Descriptive statistics were used to 
determine frequency and percentages for categorical 
variables and results were expressed either graphically or 
tabulated. Chi-square (x2) test was used and p values were 
calculated. P value < 0.05 was taken significant.
RESULTS
Mean age was 34.7 ± 18.0 years ranging from 12-75 
years. Gender distribution revealed male preponderance; 
59 (77.6%) males and 17 (22.4%) females; 3.5:1. Mean 
duration of illness before presentation to hospital was 9.7 
± 7.6ranging from 4 to 21 days. Most common clinical 
presentation was quadriparetic variety (73 out of 76; 
96.1%). Other variants included one (1.3%) Miller-Fischer, 
one (1.3%) polyneuritis cranialis and one (1.3%) 
paraparetic variant.NCS revealed AIDP as the most 
common variant (44; 57.8%) followed by AMAN (19; 
25%) and AMSAN (7; 9.2%); axonal (AMAN + 
AMSAN=26, 34.2%)(Figure 1).
 
Figure 1: NCS based defined variants of GullainBarré 
Syndrome.AIDP (Acute Inflammatory Demyelinating 
Polyneuropathy), AMAN (Acute Motor Axonal Neuropathy), 
AMSAN (Acute Motor Sensory Axonal Neuropathy).
For 5 (6.5%) patients with normal NCS, EMG revealed 
early neuropathic changes in 4 (80% of normal NCS; 5.2% 
of total) (suggesting axonal degeneration) while one (20% 
of normal NCS; 1.3% of total) proved to be Millar-Fischer 
Syndrome. The remaining one (1.3% of total) only had the 
finding of prolonged/ absent F-wave markers as the sole 
sign of proximal demyelination. Total axonal degenerative 
type accounted for (AMAN + AMSAN + axonal neuropathy 
on EMG=30) 39.4% while demyelinating (AIDP + 
prolonged/absent F-wave=45) 59.2% (Figure 2).
 
Figure 2: NCS and EMG based differentiation of variants 
of GullainBarré Syndrome.
ACD was found in 60 (78.9%) patients.Mean CSF protein 
was 131.1 ± 110 mg/dl ranging from 19 to 467 mg/dl (for 
all patients with CSF reports whether ACD or not). 
However, there was no correlation between ACD and 
NCS/EMG variants (p>0.05) (Table 1). 
Table 1: Relationship of Nerve Conduction Study variants 
with Cerebro Spinal Fluid protein
Table 1: Relationship of Nerve Conduction Study variants 
with Cerebro Spinal Fluid protein. AIDP (Acute 
Inflammatory Demyelinating Polyneuropathy), AMAN 
(Acute Motor Axonal Neuropathy), AMSAN (Acute Motor 
Sensory Axonal Neuropathy), P=prolonged, A=absent.
DISCUSSION
GBS is a common cause of acute flaccid paralysis. 
Distinguishing patients with different variants of GBS from 
one another can be of great prognostic value. Prognosis 
depends on the time of presentation and delay in 
treatment. Despite all improvements in treatment and 
supportive care, the death rate is still around5%, even in 
the best intensive care units.(6) Worldwide, the death rate 
runs slightly higher, mostly from a lack of availability of 
life-support equipment during the lengthy plateau lasting 
four to six weeks and in some cases up to one year, when 
a ventilator is needed in the worst cases.(6) Poor prognostic 
factors include age over 40 years, duration of active 
disease, high CSF protein content, rapid progression of 
motor weakness, preceding diarrheal illness, marked 
disability at presentation, electrophysiological signs of 
axonal neuropathy, requirement ofventilatory support, high 
anti-GM1 titer and poor upper-limb muscle strength.(1, 2, 6, 
7) Incidence of GBS, according to a rough estimate is much 
higher in South-Asia as compared to Europe and America 
and axonal variants account for a much larger proportion. 
(12) An epidemiologic study reported an 8-13% mortality 
rate despite ICU management in GBS, although the rate 
may be less than 5% in tertiary care centers with a team 
of medical professionals who are familiar with GBS 
management.(6) The most prevalent clinical variant, to our 
observation, wasthe quadripareticvariety in which all four 
limbs were involved usually in ascending manner.NCS 
revealed AIDP as the most common variant (44; 57.8%) 
followed by AMAN (19; 25%) and AMSAN (7; 9.2%); 
axonal (AMAN + AMSAN=26, 34.2%) (Figure 1).Upon 
review of data from local literature, Zaheer et al. in 2005 
commented on a set of 25 patients from Lahore region 
that the break down of different patterns of neuropathy 
was 36% demyelinating, 12% axonal and 52% of mixed 
variety having both demyelinating and axonal components. 
(11) They concluded that the pattern of neuropathy in GBS 
is nearly the same as reported in most European and local 
studies except Chinese endemic cases where axonal form 
is more frequent. However, other authors like Khan et al. 
did not concur with their findings.(12) They suggested that 
axonal variants constitute 40% of GBS. The variants, 
according to them were distributed as AIDP-60%, 
AMAN-30% and AMSAN-10% i-e-, axonal-40%. Their data 
set consisted of 40 patients from vicinity of Rawalpindi 
region and their results were much similar to ours when 
reported in 2010.They concluded that a high frequency of 
the axonal variants persists in Pakistan.(12) Siddiqui and 
colleaguesin 2013 studied a group of 29 GBS patients 
having AIDP-62%, AMAN-27.5% and AMSAN-10.3%(≈
axonal-38%) and concluded likewise.(13) A study by 
Yadegariet al.from Tehran, Iran done over a period of 11 
years on 121 GBS patients concluded in 2007a 
distribution pattern of 63%, 23% and 14% of AIDP, AMAN 
and AMSAN respectively (axonal-37%).(14) Meta-analysis 
reports from Europe and the United States state that 
60–80% of people with GBS have demyelinating subtype 
(AIDP) and AMAN affects only a small number 
(6–7%).These reports suggest thatin Asia and Central and 
South America, the proportion of axonal GBS is 
significantly higher (30–65%).(8) Our findings of 
demyelinating variant (AIDP + prolonged/absent 
F-wave=45) being ≈ 59% and axonal (AMAN + AMSAN 
+ axonal neuropathy on EMG=30) ≈ 40% is in 
agreement with these international reports suggesting a 
relatively poor overall prognosis of GBS in our population 
(Figure 2). Our findings support the dictum that there is 
high prevalence of axonal variants (≈40% of total) in our 
population (Asians) as compared to Western countries.(6)
We found that 6.5% NCS were normal and EMG had to be 
done in order to revealearly neuropathic changes of axonal 
degeneration in 4 (66.7% of normal NCS; 5.2% of total). 
This highlights the fact that when NCS does not reveal 
overt demyelination or axonopathy, EMG is mandatory and 
most of the time reveals neuropathic changes even earlier 
in the course of disease suggesting axonal degeneration. A 
paper by Shabbir et al.published in 2012 identified that 
out of a set of 18 patients with axonal GBS, 12 showed 
fibrillation potentials, positive sharp waves and increased 
insertional activity within 4-12 days of symptoms onset 
and 6 beyond that period.(15) Active denervation in the form 
of fibrillation potentials and positive sharp waves were 
noted frequently and decreased interference pattern in 
almost all patients. On the basis of their observations of 
finding fibrillation potentials, positive sharp waves and 
decreased interference pattern early in the course of 
disease i-e-, before two weeks of symptom onset, they 
raised the query for a possible new hyperacute or 
fulminant variant of GBS.(15) The 4 of our patients with 
normal NCS revealed similar earlier changes of axonal 
neuropathy (all NCS/EMG done within 24-72 hours and 
symptom onset in all of these 4 patients being 3-4 days 
only) supporting their idea but needs further confirmation. 
It also suggests that when clinically indicated, NCS should 
be combined by detailed EMG study especially if NCS turns 
out to be normal. In a study by Akbayramet al.done in 36 
children in 2010-11, 51.4% showed albuminocytological 
dissociation on cerebrospinal fluid examination.(6) 
According to Yadegari and colleagues, higher levels of CSF 
protein are more frequent in AIDP subtype. They 
commented that although the rise in CSF protein is more 
frequent in demyelinating variant, it may not have enough 
sensitivity to discriminate AIDP from axonal subtypes. 
Hence, the diagnosis of GBS and defining its subtypes 
should not be made based on a single finding.(14) We found 
ACD in 60 (78.9%) patients with mean CSF protein of 
131.1 ± 110 mg/dl ranging from 19 to 467 mg/dl. 
However, there was no correlation between ACD and 
NCS/EMG variants (p>0.05) (Table 1). Our findings 
therefore concur with that of Yadegariet al.(14) and further 
augments their findings signifying that NCS/EMG are not 
only essential diagnostic tools but prognostic as well by 
helping differentiate between axonal and demyelinating 
typesirrespective of whether ACD is present or not (Table 
1). Classifying patients on the basis of nerve conduction 
studies and electromyography can be helpful in guiding the 
prognosis of GBS in addition to being diagnostically 
pertinent. It helps stratify patients at beginning and thus 
help modify management plans accordingly with the hope 
of better patient outcomes. However, this classification 
should be based on a comprehensive and compact 
agreement between clinical presentation, CSF findings 
and detailed electrophysiological studies and not on a 
single factor. While high CSF is suggested by some to be a 
marker of poor patient outcomes, ADC per se does not 
differ among different NSC variants and mere presence or 
absence of ACD cannot predict axonal or demyelinating 
neuropathy which themselves are independent predictors 
of outcome. 
CONCLUSION 
AIDP is the most prevalent (58%) GBS variant in our 
population, at least in the vicinity of Islamabad. There is 
high prevalence of axonal variants (≈40% of total) as 
compared to Western countries. There is no correlation 
between ACD and NCS variants. ACD cannot be used as 
an independent predictor of NCS variant.Presence or 
absence of ACD has no definite predilection for axonal 
variant which itself warrants poor patient outcomes versus 
demyelinating type. 
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INTRODUCTION
Acute flaccid paralysis (AFP) has a wide spectrum of 
etiologies.(1,2) One such common preventable cause is 
poliomyelitis which is still being reported in Pakistan. With 
marked decline in the incidence of polio, Guillain-Barré 
syndrome is now a common cause of acute flaccid paralysis. 
Two-thirds of GBS patients develop the neurologic symptoms 
2-4 weeks after respiratory or gastrointestinal infection.(3) 
The initial symptoms are subtleparesthesias in the toes and 
fingertips, followed by lower extremity weakness that may 
ascend over hours to days to involve the arms, cranial 
nerves, and in severe cases the muscles of respiration. 
Respiratory muscle weakness is a poor prognostic sign.(3, 4, 5) 
At some point during their illness, up to 10 percent of 
patients require mechanical ventilation.(6) GBS has several 
electro physiological manifestations and variants namely 
AIDP (Acute Inflammatory Demyelinating Polyneuropathy), 
AMAN (Acute Motor Axonal Neuropathy), AMSAN (Acute 
Motor Sensory Axonal Neuropathy) or normal. Each has its 
own diagnostic and prognostic significance and guides 
management at least to some extent on individual basis.(3, 4, 
5, 6) CSF is characteristically acellular. Protein levels may be 
normal during the first week of the illness, but the majority 
will have an increase in protein if measured 2 or 3 weeks 
later, called albuminocytological dissociation (raised protein 
concentration without pleocytosis).(6) Since the knowledge 
about novel presentations of GBS is currently evolving, one 
must remain abreast not only with the worldwide spectrum 
of GBS but of its local variants, both clinical and electro 
physiological. Meanwhile, the importance of albumino 
cytological dissociationcannot be denied both diagnostically 
and prognostically.(7, 8, 9) The rationale of the study was to 
determine whether presence or absence of albumino 
cytological dissociation has any association with NCS 
findings and whether can be relied upon as an indirect 
predictor of axonal variant which warrants poor patient 
outcomes versus demyelinating. 
MATERIALS AND METHODS
This study was a single-center, observational, descriptive 
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study carried out at Department of Neurology, Pakistan 
Institute of Medical Sciences (PIMS), Islamabad, Pakistan; 
from 1st July 2013 to 30th June 2014 i-e-, 12 months 
period. Seventy six patients of GBS aged more than ≥ 12 
years (only adult population is received at our centre) were 
included and analyzed in the final data set. This study was 
an independent project of the department and was not 
funded by any pharmaceutical organization. The study was 
reviewed by ethics committee and performed in 
accordance with the ethical standards laid down in an 
appropriate version of the 2000 Declaration of Helsinki as 
well as the Declaration of Istanbul 2008. Patients fulfilling 
the inclusion criteria were enrolled after taking informed 
written consent from the patients and/ or relatives. All the 
patients were admitted when they first presented to the 
facility without delay. Criterion for GBS was ascertained 
according to Brighton Collaboration criterion for GBS 
(clinical, laboratory and NCS) and the following information 
was collected:(10) age, gender, duration of illness, clinical 
presentation and routine laboratory tests (complete blood 
counts, liver function tests, renal function tests, blood 
sugar random, serum electrolytes, urine routine 
examination, urine culture, blood cultures, arterial blood 
gases (ABGs), electrocardiogram, chest x-rays, toxicology 
screen, ESR, CPK, LDH, hepatitis screening). 
Electrodiagnostic tests i-e-, nerve conduction studies 
(NCS) and electromyography (EMG) were carried out using 
Cadwell Sierra II Wedge NCS EMG machine by a 
neurologist. Electrodiagnostic tests were performed in all 
patients and data was recorded. Lumbar puncture was 
done for CSF R/E (cerebrospinal fluid routine examination) 
in all patients consenting. CSF protein estimation with 
albuminocytological dissociation was calculated. 
Albuminocytological dissociation was defined as CSF with 
raised protein (>45mg/dl; lab reference at our centre) and 
total cell count of ≤ 10/mm3.6 Patients with alcoholism, 
any trauma affecting muscles or nerves, renal or metabolic 
dysfunctions, peripheral vascular diseases, myopathy, 
motor neuron disorders, any genetic or other disorders 
affecting nerve and muscles, CIDP (Chronic Inflammatory 
Demyelinating Polyneuropathy), diabetic peripheral 
neuropathy were excluded. Electrophysiologically, based 
on NCS, the following variants were defined: AIDP (Acute 
Inflammatory Demyelinating Polyneuropathy), AMAN 
(Acute Motor Axonal Neuropathy), AMSAN (Acute Motor 
Sensory Axonal Neuropathy) or normal. The nerve 
conduction studies were performed within 24-72 h of 
hospitalization in all cases. Needle EMG was also 
performed. At least one motor and one sensory nerve were 
tested on the upper and lower limbs. F-wave 
responseswere recorded in all the extremities. Additionally, 
routine motor conduction studies were performed on the 
median, ulnar, peroneal and tibial nerves using 
conventional procedures. Sensory nerve studies were 
performed on the median, ulnar and sural nerves. The 
amplitude of the negative phase was measured for 
compound muscle action potentials and sensory nerve 
action potentials. Patients were classified into AIDP or 
AMAN based on the existing electrodiagnostic criteria.(11) 
AMSAN was defined as the presence of AMAN pattern in 
motor nerve studies with sensory nerve action potential 
amplitude reduction more than 50% of the normal in two 
or more sensory nerves.Millar-Fischer Syndrome (MFS) 
was defined as triad of ataxia, opthamoplegia and areflexia 
without other possible causes.(6) Polyneuritis cranialis was 
defined as that only involving multiple cranial nerves while 
paraparetic as that only involving legs.(6) People were 
offered plasma exchange (PE), Intravenous 
Immunoglobulin (IVIG), PE followed by IVIG or none 
accordingly.  The data was analyzed using SPSS version 
17.0. Mean and standard deviation were calculated for 
numerical variables. Descriptive statistics were used to 
determine frequency and percentages for categorical 
variables and results were expressed either graphically or 
tabulated. Chi-square (x2) test was used and p values were 
calculated. P value < 0.05 was taken significant.
RESULTS
Mean age was 34.7 ± 18.0 years ranging from 12-75 
years. Gender distribution revealed male preponderance; 
59 (77.6%) males and 17 (22.4%) females; 3.5:1. Mean 
duration of illness before presentation to hospital was 9.7 
± 7.6ranging from 4 to 21 days. Most common clinical 
presentation was quadriparetic variety (73 out of 76; 
96.1%). Other variants included one (1.3%) Miller-Fischer, 
one (1.3%) polyneuritis cranialis and one (1.3%) 
paraparetic variant.NCS revealed AIDP as the most 
common variant (44; 57.8%) followed by AMAN (19; 
25%) and AMSAN (7; 9.2%); axonal (AMAN + 
AMSAN=26, 34.2%)(Figure 1).
 
Figure 1: NCS based defined variants of GullainBarré 
Syndrome.AIDP (Acute Inflammatory Demyelinating 
Polyneuropathy), AMAN (Acute Motor Axonal Neuropathy), 
AMSAN (Acute Motor Sensory Axonal Neuropathy).
For 5 (6.5%) patients with normal NCS, EMG revealed 
early neuropathic changes in 4 (80% of normal NCS; 5.2% 
of total) (suggesting axonal degeneration) while one (20% 
of normal NCS; 1.3% of total) proved to be Millar-Fischer 
Syndrome. The remaining one (1.3% of total) only had the 
finding of prolonged/ absent F-wave markers as the sole 
sign of proximal demyelination. Total axonal degenerative 
type accounted for (AMAN + AMSAN + axonal neuropathy 
on EMG=30) 39.4% while demyelinating (AIDP + 
prolonged/absent F-wave=45) 59.2% (Figure 2).
 
Figure 2: NCS and EMG based differentiation of variants 
of GullainBarré Syndrome.
ACD was found in 60 (78.9%) patients.Mean CSF protein 
was 131.1 ± 110 mg/dl ranging from 19 to 467 mg/dl (for 
all patients with CSF reports whether ACD or not). 
However, there was no correlation between ACD and 
NCS/EMG variants (p>0.05) (Table 1). 
Table 1: Relationship of Nerve Conduction Study variants 
with Cerebro Spinal Fluid protein
Table 1: Relationship of Nerve Conduction Study variants 
with Cerebro Spinal Fluid protein. AIDP (Acute 
Inflammatory Demyelinating Polyneuropathy), AMAN 
(Acute Motor Axonal Neuropathy), AMSAN (Acute Motor 
Sensory Axonal Neuropathy), P=prolonged, A=absent.
DISCUSSION
GBS is a common cause of acute flaccid paralysis. 
Distinguishing patients with different variants of GBS from 
one another can be of great prognostic value. Prognosis 
depends on the time of presentation and delay in 
treatment. Despite all improvements in treatment and 
supportive care, the death rate is still around5%, even in 
the best intensive care units.(6) Worldwide, the death rate 
runs slightly higher, mostly from a lack of availability of 
life-support equipment during the lengthy plateau lasting 
four to six weeks and in some cases up to one year, when 
a ventilator is needed in the worst cases.(6) Poor prognostic 
factors include age over 40 years, duration of active 
disease, high CSF protein content, rapid progression of 
motor weakness, preceding diarrheal illness, marked 
disability at presentation, electrophysiological signs of 
axonal neuropathy, requirement ofventilatory support, high 
anti-GM1 titer and poor upper-limb muscle strength.(1, 2, 6, 
7) Incidence of GBS, according to a rough estimate is much 
higher in South-Asia as compared to Europe and America 
and axonal variants account for a much larger proportion. 
(12) An epidemiologic study reported an 8-13% mortality 
rate despite ICU management in GBS, although the rate 
may be less than 5% in tertiary care centers with a team 
of medical professionals who are familiar with GBS 
management.(6) The most prevalent clinical variant, to our 
observation, wasthe quadripareticvariety in which all four 
limbs were involved usually in ascending manner.NCS 
revealed AIDP as the most common variant (44; 57.8%) 
followed by AMAN (19; 25%) and AMSAN (7; 9.2%); 
axonal (AMAN + AMSAN=26, 34.2%) (Figure 1).Upon 
review of data from local literature, Zaheer et al. in 2005 
commented on a set of 25 patients from Lahore region 
that the break down of different patterns of neuropathy 
was 36% demyelinating, 12% axonal and 52% of mixed 
variety having both demyelinating and axonal components. 
(11) They concluded that the pattern of neuropathy in GBS 
is nearly the same as reported in most European and local 
studies except Chinese endemic cases where axonal form 
is more frequent. However, other authors like Khan et al. 
did not concur with their findings.(12) They suggested that 
axonal variants constitute 40% of GBS. The variants, 
according to them were distributed as AIDP-60%, 
AMAN-30% and AMSAN-10% i-e-, axonal-40%. Their data 
set consisted of 40 patients from vicinity of Rawalpindi 
region and their results were much similar to ours when 
reported in 2010.They concluded that a high frequency of 
the axonal variants persists in Pakistan.(12) Siddiqui and 
colleaguesin 2013 studied a group of 29 GBS patients 
having AIDP-62%, AMAN-27.5% and AMSAN-10.3%(≈
axonal-38%) and concluded likewise.(13) A study by 
Yadegariet al.from Tehran, Iran done over a period of 11 
years on 121 GBS patients concluded in 2007a 
distribution pattern of 63%, 23% and 14% of AIDP, AMAN 
and AMSAN respectively (axonal-37%).(14) Meta-analysis 
reports from Europe and the United States state that 
60–80% of people with GBS have demyelinating subtype 
(AIDP) and AMAN affects only a small number 
(6–7%).These reports suggest thatin Asia and Central and 
South America, the proportion of axonal GBS is 
significantly higher (30–65%).(8) Our findings of 
demyelinating variant (AIDP + prolonged/absent 
F-wave=45) being ≈ 59% and axonal (AMAN + AMSAN 
+ axonal neuropathy on EMG=30) ≈ 40% is in 
agreement with these international reports suggesting a 
relatively poor overall prognosis of GBS in our population 
(Figure 2). Our findings support the dictum that there is 
high prevalence of axonal variants (≈40% of total) in our 
population (Asians) as compared to Western countries.(6)
We found that 6.5% NCS were normal and EMG had to be 
done in order to revealearly neuropathic changes of axonal 
degeneration in 4 (66.7% of normal NCS; 5.2% of total). 
This highlights the fact that when NCS does not reveal 
overt demyelination or axonopathy, EMG is mandatory and 
most of the time reveals neuropathic changes even earlier 
in the course of disease suggesting axonal degeneration. A 
paper by Shabbir et al.published in 2012 identified that 
out of a set of 18 patients with axonal GBS, 12 showed 
fibrillation potentials, positive sharp waves and increased 
insertional activity within 4-12 days of symptoms onset 
and 6 beyond that period.(15) Active denervation in the form 
of fibrillation potentials and positive sharp waves were 
noted frequently and decreased interference pattern in 
almost all patients. On the basis of their observations of 
finding fibrillation potentials, positive sharp waves and 
decreased interference pattern early in the course of 
disease i-e-, before two weeks of symptom onset, they 
raised the query for a possible new hyperacute or 
fulminant variant of GBS.(15) The 4 of our patients with 
normal NCS revealed similar earlier changes of axonal 
neuropathy (all NCS/EMG done within 24-72 hours and 
symptom onset in all of these 4 patients being 3-4 days 
only) supporting their idea but needs further confirmation. 
It also suggests that when clinically indicated, NCS should 
be combined by detailed EMG study especially if NCS turns 
out to be normal. In a study by Akbayramet al.done in 36 
children in 2010-11, 51.4% showed albuminocytological 
dissociation on cerebrospinal fluid examination.(6) 
According to Yadegari and colleagues, higher levels of CSF 
protein are more frequent in AIDP subtype. They 
commented that although the rise in CSF protein is more 
frequent in demyelinating variant, it may not have enough 
sensitivity to discriminate AIDP from axonal subtypes. 
Hence, the diagnosis of GBS and defining its subtypes 
should not be made based on a single finding.(14) We found 
ACD in 60 (78.9%) patients with mean CSF protein of 
131.1 ± 110 mg/dl ranging from 19 to 467 mg/dl. 
However, there was no correlation between ACD and 
NCS/EMG variants (p>0.05) (Table 1). Our findings 
therefore concur with that of Yadegariet al.(14) and further 
augments their findings signifying that NCS/EMG are not 
only essential diagnostic tools but prognostic as well by 
helping differentiate between axonal and demyelinating 
typesirrespective of whether ACD is present or not (Table 
1). Classifying patients on the basis of nerve conduction 
studies and electromyography can be helpful in guiding the 
prognosis of GBS in addition to being diagnostically 
pertinent. It helps stratify patients at beginning and thus 
help modify management plans accordingly with the hope 
of better patient outcomes. However, this classification 
should be based on a comprehensive and compact 
agreement between clinical presentation, CSF findings 
and detailed electrophysiological studies and not on a 
single factor. While high CSF is suggested by some to be a 
marker of poor patient outcomes, ADC per se does not 
differ among different NSC variants and mere presence or 
absence of ACD cannot predict axonal or demyelinating 
neuropathy which themselves are independent predictors 
of outcome. 
CONCLUSION 
AIDP is the most prevalent (58%) GBS variant in our 
population, at least in the vicinity of Islamabad. There is 
high prevalence of axonal variants (≈40% of total) as 
compared to Western countries. There is no correlation 
between ACD and NCS variants. ACD cannot be used as 
an independent predictor of NCS variant.Presence or 
absence of ACD has no definite predilection for axonal 
variant which itself warrants poor patient outcomes versus 
demyelinating type. 
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